南财智讯12月21日电，祥生医疗公告，公司股东祥鼎投资、上海御德、祥鹏投资此前披露的减持计划期 间为2025年9月22日至2025年12月21日，拟分别减持不超过1.05%、0.37%、0.30%的股份。截至2025年 12月21日，上述减持计划时间届满，三位股东均未实施减持，实际减持比例为0.00%。目前，祥鼎投资 仍持有公司4.20%股份，上海御德持有1.50%股份，祥鹏投资持有1.20%股份。 ...

截至发稿，祥生医疗市值为34亿元。 每经头条（nbdtoutiao）——大洗牌！AI手机大战开启，豆包率先放大招！苹果、谷歌"慢半拍"？业 内：苹果是"最保守的大玩家" 每经AI快讯，祥生医疗（SH 688358，收盘价：30.55元）12月21日晚间发布公告称，近日，公司收到减 持主体的告知函，截至2025年12月21日，上述减持计划时间已届满，在减持计划期限内，公司股东祥鼎 投资、上海御德、祥鹏投资未减持公司股份。 2024年1至12月份，祥生医疗的营业收入构成为：医疗器械行业占比99.88%，其他业务占比0.12%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-051 无锡祥生医疗科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持有的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医 疗"或"公司"）股东无锡祥鼎投资企业（有限合伙）（以下简称"祥鼎投资"）持有 公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以 下简称"上海御德"）持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东 无锡祥鹏投资企业（有限合伙）（以下简称"祥鹏投资"）持有公司股份 1,344,000 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 2022 年 12 月 3 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 8 月 ...

无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688358 证券简称：祥生医疗 无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会 会议资料 二〇二五年十二月 现场要求提问的股东及股东代理人，应当按照会议的议程举手示意，经会 议主持人许可后方可提问。有多名股东及股东代理人同时要求提问时，先举手 者先提问；不能确定先后时，由主持人指定提问者。 1 无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会会议资料 无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 会议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》以及《无锡祥生医疗科技股份有限公司章程》《无锡 祥生医疗科技股份有限公股东会议事规则》等相关规定，无锡祥生医疗科技股 份有限公司（以下简称"公司"）特制定本次股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次会议的严肃性和正常 ...

Group 1 - The company, 瑞奇智造, announced that it will hold its second extraordinary general meeting of shareholders on December 18, 2025 [2] - The agenda includes a proposal to change the accounting firm [2]

Group 1: China Civil Aviation Information Network (00696) - The company is a leading GDS provider globally and the largest in China, with a global market share of approximately 28% and a domestic market share of about 95% [10] - The company's performance is highly correlated with the growth of the civil aviation industry, with expected flight bookings reaching 732 million in 2024, surpassing the 2019 peak [10] - The launch of the "official direct sales platform" in July 2025 positions the company to enter the trillion-yuan OTA market, aiming to reduce reliance on traditional OTAs [10] - The company is projected to achieve net profits of 2.21 billion, 2.43 billion, and 2.65 billion yuan from 2025 to 2027, with a maintained "buy" rating based on recovery in the civil aviation sector [10] Group 2: Xiangsheng Medical (688358) - Xiangsheng Medical has focused on ultrasound technology since its establishment in 1996, holding over 400 intellectual property rights and offering a comprehensive range of ultrasound products [11] - The company aims to leverage its "portable + intelligent" advantage, with products like SonoFamily series that include high-end and portable ultrasound devices, enhancing its competitive edge [11] - The company is expected to achieve revenues of 517 million, 620 million, and 744 million yuan from 2025 to 2027, with net profits projected at 146 million, 182 million, and 229 million yuan, respectively, maintaining a "buy" rating [13] Group 3: CIMC Enric (03899.HK) - CIMC Enric is a clean energy equipment platform under CIMC, focusing on LNG transportation, storage, and processing, with a projected net profit CAGR of 17% from 2020 to 2024 [13] - The company has a robust order backlog of 30.8 billion yuan, with 27.3 billion yuan in clean energy equipment orders, benefiting from the LNG market's growth [14] - The company is expected to achieve net profits of 1.13 billion, 1.47 billion, and 1.76 billion yuan from 2025 to 2027, with a "buy" rating based on a 29% upside potential from its current valuation [15] Group 4: PVA Industry (皖维高新 600063) - The company has established a comprehensive PVA industrial chain, with a focus on cost advantages and long-term growth potential, aiming to expand into high-value new materials [23] - The company is positioned to benefit from a recovery in demand for PVA products, with a projected increase in production capacity and profitability in the coming years [23] - The company is expected to achieve revenues of 8.064 billion, 8.881 billion, and 9.768 billion yuan from 2025 to 2027, with net profits projected at 473 million, 622 million, and 862 million yuan, respectively, maintaining an "overweight" rating [25] Group 5: Social Services Industry - The introduction of spring and autumn holidays has stimulated tourism demand, with significant increases in travel and spending during these periods [26] - The winter "snow holiday" policy has also contributed to the recovery of the ice and snow tourism industry, with various incentives driving participation [26] - The overall service consumption is expected to benefit from government policies aimed at boosting demand, with a focus on tourism and related sectors [27]

Core Viewpoint - Xiangsheng Medical (688358) has completed the grant registration of its 2025 restricted stock incentive plan, issuing 150,000 shares at a price of 16.50 yuan per share, which will not affect the company's control [1]. Group 1: Stock Performance - As of December 15, 2025, Xiangsheng Medical's stock closed at 29.82 yuan, up 0.81% from the previous trading day, with a total market capitalization of 3.344 billion yuan [1]. - The stock opened at 29.58 yuan, reached a high of 30.18 yuan, and a low of 29.40 yuan, with a trading volume of 22.3845 million yuan and a turnover rate of 0.67% [1]. Group 2: Incentive Plan Details - The company granted 150,000 restricted shares to 16 incentive recipients, with the stock sourced from a buyback of 148,924 shares and a directed issuance of 1,076 shares [1]. - The total share capital increased from 112,124,537 shares to 112,125,613 shares, with no change in control of the company [1]. - The lock-up period for the shares is set for 12 months and 24 months, with 50% of the shares being released from the lock-up in two phases [1].

Group 1 - Anbotong plans to issue H-shares and list on the Hong Kong Stock Exchange, with the board authorizing management to start preparations within 12 months [1] - Xiangsheng Medical proposes a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [2] - Junshi Biosciences receives FDA approval for clinical trials of JS212, a dual-specific antibody-drug conjugate for treating advanced solid tumors [3] Group 2 - Zhonghuan Environmental plans to raise up to 300 million yuan by issuing shares to a specific entity, with funds allocated for working capital and bank loan repayment [4] - Guao Technology announces a change in actual control to Xu Yinghui, with stock resuming trading on December 15 [5] - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol project in Heilongjiang [6] Group 3 - Shanghai Airport reports a 15.47% year-on-year increase in passenger throughput at Pudong International Airport for November [7] - Innovent Biologics achieves primary endpoint in a Phase IIb study of Obinutuzumab for systemic lupus erythematosus, with plans for a Phase III trial [8] - Saiyi Information leads a national major science and technology project on intelligent manufacturing systems and robotics [9] Group 4 - Yipin Hong's Qinxing Qingjie oral solution is approved as a national second-level protected traditional Chinese medicine [10] - Yipin Hong's stake in US-based Arthrosi Therapeutics is set to be acquired by Sobi for a total of up to 950 million USD [11] - Pudong Jinqiao announces the resignation of Chairman Wang Ying due to job transfer [12] Group 5 - Jiaze New Energy plans to invest in two wind power projects with a total estimated investment of approximately 2.366 billion yuan [13] - Jinpan Technology receives approval from the CSRC for issuing convertible bonds to unspecified investors [14] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for 356 million yuan [15] Group 6 - Jiuan Medical's US subsidiary receives pre-market notification from the FDA for multiple testing products [16][17] - Changfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [18] - Chenfeng Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [19][20][21][22]

新京报贝壳财经讯 12月14日，祥生医疗发布公告称，2025年前三季度公司拟向全体股东每10股派发现 金红利3元（含税），合计拟派发现金红利3356.24万元（含税），本次利润分配不进行资本公积转增股 本，不送红股，尚需提交公司2025年第三次临时股东会审议通过后方可实施。 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-048 无锡祥生医疗科技股份有限公司 关于变更公司注册资本、修订《公司章程》 并办理工商变更登记的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于2025年12月12日召开第三届董事会第十七次会 议，审议通过了《关于变更公司注册资本、修订〈公司章程〉并办理工商变更登记的议案》。具体情况 如下： 一、公司注册资本变更相关情况 根据公司2025年第二次临时股东会授权，公司于2025年10月23日召开了第三届董事会第十六次会议、第 三届董事会薪酬与考核委员会第六次会议，审议通过了《关于向2025年限制性股票激励计划激励对象授 予限制性股票的议案》，确定2025年10月23日为授予日，以16.50元/股的授予价格向17名激励对象授予 160,000股限制性股票。具体内容参见公司于2025年10月24日刊登于上海证券交易所网站 （www.sse.com.cn）的《无锡祥生医疗科技股份有限公司关于向2025年限制性股票 ...